UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
 
Date of Report (Date of Earliest Event Reported):
 
January 5, 2017
________________________
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________
Delaware
001-32335
 
88-0488686
(State or other jurisdiction
of incorporation)
(Commission
File Number)
 
(IRS Employer
Identification No.)
11388 Sorrento Valley Road, San Diego, California
92121
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
 
(858) 794-8889
Not Applicable
(Former name or former address, if changed since last report)
  _________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 









Item 8.01. Other Events.

On January 5, 2017, Halozyme Therapeutics, Inc. issued a press release announcing topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study, a randomized, multi-center clinical trial of lead investigational drug PEGPH20 in combination with ABRAXANE® (nab-paclitaxel) and gemcitabine in stage IV pancreatic cancer patients. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.          Description

99.1            Press release dated January 5, 2017
 
        
 







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
 
 
HALOZYME THERAPEUTICS, INC.
  
 
 
 
 
January 5, 2017
 
By:
 
/s/ Harry J. Leonhardt Esq.
 
 
Name:
 
Harry J. Leonhardt, Esq. 

 
 
Title:
 
Senior Vice President, General Counsel,
Chief Compliance Officer and Corporate Secretary









Exhibit Index

 
 
 
Exhibit No.
 
Description
 
 
 
99.1
 
Press release dated January 5, 2017




Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Halozyme Therapeutics Charts.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Halozyme Therapeutics Charts.